Alexander Shulgin chemist who discovered Ecstasy drug dies Oakland, US

Alexander Shulgin, discoverer of drug Ecstasy dies at 88

5:32 AM, 9th June 2014
Alexander Shulgin chemist discoverer of drug Ecstasy
© Washington Post News.

NEW YORK, US: Alexander Shulgin, a chemist who specialized in the creation of and experimentation with mind-altering substances, and who introduced the controversial drug popularly known as Ecstasy for potential therapeutic use, dies at his residence in Lafayette, California, east of Oakland, US. He was 88.

His work resulted in patents - his drugs have been used in treating hypertension, reducing nicotine cravings and addressing senility, among other things - but it has also been appropriated by recreational users, sometimes to dangerous effect. In 1967, one of his compounds, popularly known as STP, whose effects include hallucinations and a sense that time has slowed down, was deployed in high doses by San Francisco thrill seekers, sending dozens, if not hundreds, to emergency rooms with fears that they would never return to normal.

Shulgin is probably best known for his resynthesis of the drug MDMA, which had first been patented in 1914 by the German drug manufacturer Merck and later abandoned because no appropriate use of it had emerged.

Some therapists indeed found that it encouraged rapid improvement in some patients, but after MDMA migrated to recreational use - and became known as Ecstasy, or X - the DEA classified it as a Schedule I drug. It was banned in the mid-1980s, at a time when Nancy Reagan’s “Just Say No” campaign against drug use was at its peak. In recent years research on its potential uses (for example, in the treatment of traumatized war veterans) has re-emerged.

Shulgin was the author of five books that documented his work, including two, self-published in the 1990s, that focus on particular families of chemical compounds – “PiHKAL,” short for “phenethylamines I Have Known and Loved,” and “TiHKAL” (Tryptamines I Have Known and Loved). Both describe his work in detail and his experiences in sampling it.


© The New York Times News Service



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Bimetallic nanoparticle catalyst to improve industrial process

CALIFORNIA, US: Atomic-scale snapshots of a bimetallic nanoparticle catalyst in action have provided insights that could help improve the industrial p ...

Read more
Altana expands production capacity in US

WESEL, GERMANY, CONNECTICUT, US: Altana, the specialty chemicals group, announced the grand opening of its BYK USA Inc expanded facility in Wallingfor ...

Read more
Evonik opens application technology centre in Taiwan

ESSEN, GERMANY: Evonik Industries inaugurated a new application technology centre (ATC) for electronic solutions in Hsinchu, Taiwan. To serve customer ...

Read more
Brenntag to invest in ultra high temperature laboratory in Vietnam

MULHEIM AN DER RUHR, GERMANY/HO CHI MINH CITY, VIETNAM: Brenntag, the global market leader in chemical distribution, has invested in an Ultra High Tem ...

Read more
Laticrete to acquire DuPont’s surface care business

BETHANY/WILMINGTON, US: Laticrete has reached a definitive agreement with DuPont to purchase the DuPont Surface Care business. The transaction is expe ...

Read more
Short carbon nanotubes delivers drug to pancreatic cancer cells

HOUSTON, US: According to researchers at Rice University and the University of Texas MD Anderson Cancer Centre, short, customized carbon nanotubes hav ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X